Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes

This trial compared once-weekly dulaglutide, a GLP-1 receptor agonist, with placebo for glycemic control in youths with type 2 diabetes who may have been receiving metformin or basal insulin. Dulaglutide was superior at 26 weeks.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 387; no. 5; pp. 433 - 443
Main Authors Arslanian, Silva A., Hannon, Tamara, Zeitler, Philip, Chao, Lily C., Boucher-Berry, Claudia, Barrientos-Pérez, Margarita, Bismuth, Elise, Dib, Sergio, Cho, Jang Ik, Cox, David
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 04.08.2022
Subjects
Adolescent Medicine
Age
and Inclusion
and Inclusion General
Antidiabetics
Diabetes
Diabetes mellitus (non-insulin dependent)
Diversity
Endocrinology
Equity
Fasting
GLP-1 receptor agonists
Glucagon
Glucagon-like peptide 1
Glucose
Hemoglobin
Hypoglycemia
Insulin
Insulin resistance
Metformin
Obesity
Pediatrics
Placebos
Statistical analysis
Teenagers
Thyroid gland
Online AccessGet full text
ISSN0028-4793
1533-4406
1533-4406
DOI10.1056/NEJMoa2204601

Cover

More Information
Summary:This trial compared once-weekly dulaglutide, a GLP-1 receptor agonist, with placebo for glycemic control in youths with type 2 diabetes who may have been receiving metformin or basal insulin. Dulaglutide was superior at 26 weeks.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2204601